Cardiac arrest & resuscitation
Levosimendan in Cardiac Arrest ( Levosimendan in Cardiac Arrest (LeiCA) ): Protocol for a Randomized, Double‐Blind, Phase II Clinical Trial
Study context
- Population
- Adults 18–75 years with witnessed, nontraumatic, refractory out-of-hospital cardiac arrest (OHCA) in Stockholm County, Swedenplanned
- Participants
- 40 adults
- Planned comparison
- Levosimendan 2.5 mg IV bolus vs placebo during CPR, adjunct to ALS
- Levosimendann = 30
- Placebon = 10reference
- Primary endpoint
- 30-day survival
- Follow-up
- 30 days
Methodological detailsphase II, pilot, investigator-initiated, double-blind, placebo-controlled, single-centre, 3:1 randomisation
- Phase II
- Pilot
- Investigator-initiated
- Double-blind
- Placebo-controlled
- Single-centre
- 3:1 randomisation
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Levosimendan in Cardiac Arrest ( LeiCA ): Protocol for a Randomized, Double‐Blind, Phase II Clinical Trial. Acta Anaesthesiol Scand. Published 24 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →